Skip to main content
TipRanks
Go Ultimate75% OFF

Arcturus Therapeutics (ARCT) AI Stock Analysis

2,166 Followers
ARCT

Arcturus Therapeutics

(NASDAQ:ARCT)

Select Model
Rating:49Neutral
Price Target:$8.50â–²(2.29% Upside)
Action:reiterated
Date:11/16/26

ARCT scores below average primarily due to weak financial performance (ongoing losses and negative free cash flow) and bearish technicals (price below major moving averages with negative MACD). Partially offsetting these are constructive earnings-call updates on clinical progress and runway through 2028, plus a supportive Meiji strategic investment at a large premium, while valuation remains constrained by unprofitability and no dividend support.

Positive Factors
Strategic partnership expansionThe expanded Meiji relationship provides external funding and a commercialization partner for ARCT-154, while assigning development costs to Meiji. This can extend Arcturus’s reach and reduce internal execution demands, creating durable strategic support beyond a single financing event.
Negative Factors
Persistent cash burnSustained negative operating and free cash flow shows that current operations do not fund development internally. Continued cash consumption can reduce financial flexibility over time, increase reliance on partnerships or financing, and make execution more sensitive to clinical and commercial outcomes.

Arcturus Therapeutics (ARCT) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%ARCT+40.85%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$239.51M
Dividend Yield
―
Average Volume (3M)
993.01K
Price to Earnings (P/E)
-2.7
Beta (1Y)
2.26
Revenue Growth
-74.84%
EPS Growth
-25.04%
Country
US
Employees
109
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Arcturus Therapeutics Business Overview & Revenue Model

Company Description

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its nota...

How the Company Makes Money

Arcturus primarily makes money through (1) collaboration and licensing arrangements and (2) to a lesser extent, other operating revenues typical of clinical-stage biopharma companies; it may also generate interest income from its cash and investments...

Arcturus Therapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-11.22%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with encouraging ARCT-810 clinical data, a reported 38-fold LUNAR 2.0 potency improvement, progress in the ARCT-032 and ARCT-2601 programs, expanding pipeline capabilities and a cash runway through year-end 2028. The main negatives were the significant year-to-date revenue decline, higher year-to-date net loss, reduced cash balance and uncertainty around the timing of a potential ARCT-032 Phase III start.

Positive Updates

Positive ARCT-810 Phase II Results in OTC Deficiency
ARCT-810 demonstrated meaningful biomarker activity at the 0.3 and 0.5 milligram per kilogram dose levels, reducing and/or maintaining first morning fasting ammonia within the normal range, including during increased protein intake. Glutamine levels were reduced in all participants, with the 0.5 milligram per kilogram dose achieving mean glutamine concentrations within the normal range during treatment. The program was generally safe and well tolerated.

Negative Updates

Year-to-Date Revenue Decline
Revenue for the first nine months of 2026 was $23.3 million versus $74.8 million in the comparable 2025 period, a decrease of approximately 69%. The decline was primarily attributable to revenue recognized under the CSL Seqirus collaboration before its termination and lower BARDA grant revenue.

Company Guidance

Arcturus expects enrollment in the ARCT-032 Phase II study to be completed by year-end, with Cohort 4 evaluating 10 milligrams administered by inhalation for 12 weeks in up to 20 adults, primarily Class I CF subjects, full Cohort 4 data planned for presentation in the second quarter of 2027, and CF top line data available before the full data presentation; the go/no-go decision timing has not been guided. The company plans to initiate Phase II dosing of ARCT-2601 in the first quarter of 2027, enrolling upwards to 6 subjects ages 12 and older, with top line data in the second half of 2027 and the starting dose being a dose previously tested with 810. Arcturus currently plans to submit an IND for its PKU program in the second half of 2027, expects commercial activities for KOSTAIVE in Europe and the United Kingdom in 2027 while pursuing a partner for the U.S. region, and expects its cash runway to extend through year-end 2028.

Arcturus Therapeutics Financial Statement Overview

Summary

Overall fundamentals are pressured by persistent losses and cash burn: TTM net loss (~-$78.1M) and negative operating/free cash flow (~-$62.6M) indicate the business is not self-funding. The balance sheet is a relative bright spot with low leverage (~0.11x debt-to-equity), but equity/assets have been trending down and ROE is deeply negative, signaling ongoing capital consumption.

Income Statement

24Negative

Balance Sheet

63Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue24.95M67.22M138.39M157.75M205.75M12.36M
Gross Profit24.29M64.20M138.39M157.75M205.75M12.36M
EBITDA-77.00M-62.76M-77.40M-24.16M15.17M-199.81M
Net Income-87.24M-65.78M-80.94M-29.73M9.35M-203.67M
Balance Sheet
Total Assets215.32M271.15M344.07M429.40M450.39M392.81M
Cash, Cash Equivalents and Short-Term Investments184.82M230.91M237.03M292.00M391.88M370.49M
Total Debt21.86M25.00M28.55M30.22M94.75M69.15M
Total Liabilities46.59M57.16M103.09M150.89M180.07M164.60M
Stockholders Equity168.73M213.99M240.98M278.51M270.31M228.21M
Cash Flow
Free Cash Flow-62.67M-74.50M-60.40M-21.00M24.27M-138.45M
Operating Cash Flow-62.48M-74.27M-59.75M-18.10M31.99M-135.04M
Investing Cash Flow87.34K-230.00K-648.00K-2.90M-7.73M-3.41M
Financing Cash Flow11.99M13.38M5.42M-24.09M-2.86M48.02M

Arcturus Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price8.31

Price Trends

50DMA12.28Negative
100DMA10.52Negative
200DMA9.11Negative

Market Momentum

MACD-0.95Positive
RSI36.74Neutral
STOCH5.43Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARCT, the sentiment is Negative. The current price of 8.31 is below the 20-day moving average (MA) of 10.10, below the 50-day MA of 12.28, and below the 200-day MA of 9.11, indicating a bearish trend. The MACD of -0.95 indicates Positive momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 5.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARCT.

Arcturus Therapeutics Risk Analysis

Arcturus Therapeutics disclosed 63 risk factors in its most recent earnings report. Arcturus Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.The termination of our collaboration with CSL Seqirus requires us to advance, fund, and seek partners for our vaccine programs, and subjects us to additional risks and uncertainties.Q2, 2026
2.Geopolitical risks associated with ongoing wars and armed conflicts could have an adverse impact on our business, financial condition and results of operations, including our clinical trials.Q1, 2026
3.A potential separation of CSL Seqirus could disrupt our collaboration and materially harm our business.Q4, 2025

Arcturus Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ARCT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KRROKRRO55Neutral$174.45M-1.42-117.05%―-82.47%3.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ARCTARCT49Neutral$239.52M-2.72-46.79%―-74.84%-25.04%
SLNSLN48Neutral$1.23B-7.26-56.32%―――
EDITEDIT47Neutral$288.62M-3.08-130.43%―7.43%74.00%
BNTCBNTC45Neutral$308.46M-8.45-27.60%――-12.64%
PRQRPRQR42Neutral$166.52M-2.84-70.45%―19.49%-4.53%

* Healthcare Sector Average

Performance Comparison

0%100%200%ARCTPRQRBNTCEDITKRROSLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ARCT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ARCTArcturus Therapeutics8.312.2737.58%
PRQRProQR Therapeutics BV1.18-0.85-41.87%
BNTCBenitec Biopharma8.54-4.56-34.81%
EDITEditas Medicine Inc.1.87-0.65-25.79%
KRROKorro Bio, Inc.12.716.3098.28%
SLNSilence Therapeutics Plc19.8013.37207.93%

Arcturus Therapeutics Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Arcturus Expands Meiji Collaboration Through $50 Million Investment

Positive
Nov 16, 2026

On November 16, 2026, Arcturus entered a securities purchase agreement selling Meiji 2,466,395 shares for $50.0 million at $20.27 per share, an 80% premium to the average closing price over the 30 trading days through and including November 11; the s...

Business Operations and StrategyRegulatory Filings and Compliance

Arcturus Showcases Phase 2 ARCT-810 Data, mRNA Advances

Positive
Sep 23, 2026

On September 23, 2026, Arcturus Therapeutics presented an overview of Phase 2 clinical data for its investigational therapy ARCT-810 and provided an update on its mRNA delivery platform. The company also issued a press release summarizing these mater...

Business Operations and StrategyProduct-Related Announcements

Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium

Positive
Aug 25, 2026

On August 25, 2026, Arcturus Therapeutics will present a poster on ARCT-810, its mRNA therapy candidate for ornithine transcarbamylase deficiency, at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, F...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026